【摘要】：目的探討臨床藥師對經(jīng)皮冠狀動脈介入治療(PCI)術(shù)后患者的藥學(xué)監(jiān)護(hù),為心內(nèi)科臨床藥師開展藥學(xué)服務(wù)提供參考。方法臨床藥師對1例PCI術(shù)后患者反復(fù)出現(xiàn)支架內(nèi)再狹窄的因素進(jìn)行分析,分別從抗血小板藥物治療的基因多態(tài)性、術(shù)后血脂和血糖的控制、用藥依從性教育和出院后電話隨訪等方面提出建議并進(jìn)行藥學(xué)監(jiān)護(hù)。結(jié)果與結(jié)論臨床藥師為臨床醫(yī)師對該患者藥物治療方案的調(diào)整提供了合理的建議并對其實施藥學(xué)監(jiān)護(hù),半年后電話回訪未出現(xiàn)心血管不良事件和藥物不良反應(yīng),為其安全有效地用藥提供保障,并提高用藥依從性。
[Abstract]:Objective to explore the pharmacological monitoring of patients after percutaneous coronary intervention (PCI) by clinical pharmacists, and to provide reference for pharmacists in cardiology. Methods Clinical pharmacists analyzed the factors of recurrent restenosis in stents in one patient after PCI, and analyzed the genetic polymorphisms of antiplatelet drug therapy, the control of blood lipid and blood glucose respectively. Suggestions on drug compliance education and telephone follow-up after discharge were put forward and pharmacological monitoring was carried out. Results and conclusion Clinical pharmacists provided reasonable suggestions for clinicians to adjust the drug treatment plan of the patients and carried out pharmacological monitoring. No adverse cardiovascular events or adverse drug reactions were observed by telephone half a year later. To provide security for its safe and effective drug use, and improve drug compliance.
【作者單位】： 蘇州大學(xué)附屬第一醫(yī)院藥學(xué)部;南京醫(yī)科大學(xué)附屬蘇州醫(yī)院藥學(xué)部;
【基金】：國家自然科學(xué)基金資助項目(81173132)
【分類號】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張倩;朱君榮;朱余兵;;糖尿病合并高血壓患者的藥學(xué)監(jiān)護(hù)[J];中國藥師;2012年06期

2 盧浙文;;急性重癥病毒性心肌炎的藥學(xué)監(jiān)護(hù)[J];海峽藥學(xué);2012年07期

3 吳s，

本文編號：2379440